Skip to main content
Fig. 4 | Journal of Neurodevelopmental Disorders

Fig. 4

From: A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX)

Fig. 4

Individual patient changes from baseline to week 12 in ABC-CFXS Social Avoidance subscale scores: ≥ 90% methylation group. Distribution of changes in ABC-CFXS SA subscale scores at 12 weeks in the patients who had ≥ 90% methylation of the promoter region of the FMR1 gene. Each circle represents one patient in the study. The mode for the distribution of each group is shown in the figure

Back to article page